CTN-0028: Osmotic-Release Methylphenidate for ADHD in Adolescents with Substance Use Disorders
Paula Riggs, MD
University of Colorado at Denver
Health Sciences Center
T. John Winhusen, PhD
University of Cincinnati
Addiction Sciences Division
The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.
OROS-MPH did not show greater efficacy than placebo for ADHD or on reduction in substance use in adolescents concurrently receiving individual CBT for co-occurring SUD. However, OROS-MPH was relatively well tolerated and was associated with modestly greater clinical improvement on some secondary ADHD and substance outcome measures.
Primary Outcomes Article: Riggs PD, et al. Randomized Controlled Trial of Osmotic-Release Methylphenidate with CBT in Adolescents with ADHD and Substance Use Disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2011 (in press). [get article]
- CTN-0028-A-1: Does Methylphenidate Treatment for ADHD Increase the Rate of Smoking in Adolescents with Comorbid ADHD, Substance Use Disorder, and Nicotine Dependence?
- CTN-0028 Study Protocol
- Publications in the Library about CTN-0028
- Study data from NIDA Data Share
- ClinicalTrials.gov (NCT00264797)
- NIDA protocol page
All Participating Nodes: